Amgen, Inc. (NASDAQ:AMGN)

biotech word cloud

Short Sellers Become More Selective on Major Biotechs

The short interest data are out for the June 30 settlement date. Biotech companies are considered a riskier group of stocks, with big potential upside and big potential downside. In ...
Read Full Story »
Pills and tablets

Biotechs With Drug Pipelines Closest to Zero Valuation

As biotech valuations and share price remain muted versus historic trends, investors have been evaluating which of the best biotech companies are offering the most upside. Other investors are looking ...
Read Full Story »
automatic inspection machine

5 Top Biotechs Where Future Multi-Billion Dollar Drug Pipelines are Valued Almost at Zero

Sometimes market volatility and outside shocks create a rift between market prices and real value. That may currently be the case in the largest stocks in the biotech sector within health ...
Read Full Story »
biotech word cloud

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the June 15 settlement date. Biotech companies are considered a riskier group of stocks, with big potential upside and big potential downside. After ...
Read Full Story »
biotech word cloud

Short Sellers Become More Selective on Major Biotechs

The short interest data are out for the May 31 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Test tubes

Short Sellers Grow More Selective on Major Biotechs

The short interest data are out for the May 13 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Test tubes

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the April 29 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Prescription drugs

Analysts Adjust Predictions on Medivation Buyout Price

One time when missing earnings estimates doesn't matter much is when there is bidding war for the company. That's the position that Medivation Inc. (NASDAQ: MDVN) found itself in after ...
Read Full Story »
biotech word cloud

Analysts Make Major Changes to Top Biotech Ratings

At different times of the year, certain sectors come alive or slow down. Typically each year, the first quarter is the slowest for the biotechs, so many analysts tend to ...
Read Full Story »
biotech word cloud

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the April 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
biotech word cloud

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the March 31 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Pills and tablets

Regeneron and Sanofi Plan to Appeal Amgen Patent Verdict

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) saw its shares halted on Wednesday afternoon after a jury ruled in favor of Amgen Inc. (NASDAQ: AMGN) on a cholesterol drug patent. However, Regeneron ...
Read Full Story »
biotech word cloud

Short Sellers Back Off of Major Biotechs

The short interest data are out for the February 29 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
biotech word cloud

Why Citi Sees Huge Upside in 4 Top Biotechs Now

If there was one sector inside of a broader health care theme that performed well through much of 2015, it was biotech. That was then, and this is now. A ...
Read Full Story »
graph

Short Interest Rises Across the Board in Major Biotechs

The short interest data are out for the February 12 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »